FDA Panel Supports HeartWare VAD, Despite Trial Shortcomings

Benefits of HeartWare system, as well as the prospect of adding a competitive device to a market currently dominated by a single product, overshadow uncertainties from missing data, panelists vote.

More from Regulation

More from Policy & Regulation